Remus Pharmaceuticals (NSE:REMUS) EV-to-EBIT : 27.42 (As of May. 30, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Remus Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Remus Pharmaceuticals's Enterprise Value is ₹12,278 Mil. Remus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹448 Mil. Therefore, Remus Pharmaceuticals's EV-to-EBIT for today is 27.42.

The historical rank and industry rank for Remus Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

NSE:REMUS' s EV-to-EBIT Range Over the Past 10 Years
Min: 26.04 Med: 45.88 Max: 243.49
Current: 27.42

During the past 4 years, the highest EV-to-EBIT of Remus Pharmaceuticals was 243.49. The lowest was 26.04. And the median was 45.88.

NSE:REMUS's EV-to-EBIT is ranked worse than
82.98% of 94 companies
in the Medical Distribution industry
Industry Median: 12.82 vs NSE:REMUS: 27.42

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Remus Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 was ₹15,410 Mil. Remus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹448 Mil. Remus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2.91%.

Remus Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Remus Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remus Pharmaceuticals EV-to-EBIT Chart

Remus Pharmaceuticals Annual Data

Trend

Mar20

Mar21

Mar22

Mar24

EV-to-EBIT

32.16

Remus Pharmaceuticals Semi-Annual Data
	Mar20	Mar21	Mar22	Sep23	Mar24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	32.16	-

Competitive Comparison of Remus Pharmaceuticals's EV-to-EBIT

For the Medical Distribution subindustry, Remus Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Remus Pharmaceuticals's EV-to-EBIT Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Remus Pharmaceuticals's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Remus Pharmaceuticals EV-to-EBIT Calculation

Remus Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	12277.598	/	447.701
	=	27.42

Remus Pharmaceuticals's current Enterprise Value is ₹12,278 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹448 Mil.

Remus Pharmaceuticals (NSE:REMUS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Remus Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 )	=	EBIT	/	Enterprise Value (Q: Sep. 2024 )
	=	447.701	/	15410.3744
	=	2.91 %

Remus Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2024 was ₹15,410 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Remus Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was ₹448 Mil.

Remus Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Remus Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Remus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Remus Pharmaceuticals Ltd (NSE:REMUS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054

Website

https://www.remuspharma.com

Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.

Remus Pharmaceuticals Headlines

No Headlines